Endocrine resistance in breast cancer: biological mechanisms and clinical implications to develop new treatment strategies

2013 ◽  
Author(s):  
Katia Cannita
Keyword(s):  
Breast Cancer ◽  
Endocrine Resistance ◽  
Treatment Strategies ◽  
Clinical Implications ◽  
Biological Mechanisms ◽  
New Treatment

scholarly journals Biological mechanisms and clinical implications of endocrine resistance in breast cancer

The Breast ◽  
2011 ◽  
Vol 20 ◽  
pp. S42-S49 ◽  
Author(s):  
Mario Giuliano ◽  
Rachel Schiff ◽  
C. Kent Osborne ◽  
Meghana V. Trivedi
Keyword(s):  
Breast Cancer ◽  
Endocrine Resistance ◽  
Clinical Implications ◽  
Biological Mechanisms

scholarly journals Genetic Mutations Associated with Hormone-Positive Breast Cancer in Ethiopian Women

2020 ◽  
Author(s):  
Alyssa D. Schwartz ◽  
Afua Adusei ◽  
Solomon Tsegaye ◽  
Christopher A. Moskaluk ◽  
Sallie S. Schneider ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African Americans ◽  
Cancer Patients ◽  
Tumor Tissue ◽  
Treatment Strategies ◽  
Breast Cancer Diagnosis ◽  
Breast Cancer Patients ◽  
European Descent ◽  
Matrix Encoding ◽  
New Treatment

AbstractIn Ethiopia, a breast cancer diagnosis is associated with a prognosis significantly worse than that of Europe and the US. Further, patients presenting with breast cancer in Ethiopia are far younger, on average, and patients are typically diagnosed at very late stages, relative to breast cancer patients of European descent. Emerging data suggest that a large proportion of Ethiopian patients have hormone-positive (ER +) breast cancer. This is surprising given 1) the aggressive nature of the disease, 2) that African Americans with breast cancer frequently have triple negative breast cancer (TNBC), and 3) these patients typically receive chemotherapy, not hormone-targeting drugs. To further examine the similarity of Ethiopian breast tumors to those of African Americans or of those of European descent, we sequenced matched normal and tumor tissue from Ethiopian patients from a small pilot collection. We identified mutations in 615 genes across all three patients, unique to the tumor tissue. Across this analysis, we found far more mutations shared between Ethiopian patient tissue and White patients (103) than we did comparing to African Americans (3). Several mutations were found in extracellular matrix encoding genes with known roles in tumor cell growth and metastasis. We suggest future mechanistic studies on this disease focus on these genes first, toward finding new treatment strategies for breast cancer patients in Ethiopia.

Asymptomatic versus symptomatic metastatic breast cancer: Potential effects on prognosis and treatment strategies.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12568-e12568
Author(s):  
Sayaka Kuba ◽  
Kosho Yamanouchi ◽  
Shigeto Maeda ◽  
Hiroshi Yano ◽  
Shigeki Minami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Surgery ◽  
Endocrine Resistance ◽  
Treatment Strategies ◽  
Metastatic Breast ◽  
Multicenter Cohort Study ◽  
Disease Free Interval ◽  
Median Period ◽  
Life Threatening

e12568 Background: Early breast cancer (BC) patients in Japan can receive a follow-up CT scan, which can diagnose asymptomatic metastatic (M)BC. How symptomatic and asymptomatic MBC differ regarding prognosis and whether treatment strategies should differ is unclear. Methods: A retrospective, multicenter, cohort study was performed. We reviewed records of MBC women treated at four institutions between 2008 and 2018. Follow-up CTs were not routinely performed. Patients were divided into three BC subtypes: Luminal (ER+, PgR+, or both, but HER2-), HER2 (HER2+), and triple negative (TN) (ER-, PgR-, HER2-). Results: Of 205 MBC patients, 120 were luminal, 51 HER2, and 34 TN. Ninety were diagnosed with symptomatic and 115 with asymptomatic MBC. Symptomatic MBC patients had the following symptoms: locoregional metastasis (43%), bone pain (25%), cough or dyspnea (16%), and brain-related symptoms (10%). Diagnosis of asymptomatic MBC was based on follow-up imaging (71%) and elevated tumor markers (27%). The proportion of the patients with symptomatic MBC were different in each subtype: 38% luminal, 45% HER2, and 65% TN (p = 0.02). Among luminal patients, median overall survival (OS) after metastasis was longer for those with asymptomatic versus symptomatic MBC (62 vs 41 M, respectively; p = 0.04), although disease-free interval (48 vs 54 M, respectively; p = 0.40) and OS after breast surgery (119 vs 126 M, respectively; p = 0.93) did not differ significantly. Conversely, among TN patients, those with asymptomatic MBC had significantly longer median OS after metastasis and after breast surgery. Although the median period of cumulative endocrine therapy after metastasis did not differ between groups, luminal BC patients with asymptomatic MBC received chemotherapy longer than those with symptomatic MBC (20 vs 12 M, respectively; p = 0.02). Most patients switched to chemotherapy because of endocrine resistance without life threatening disease. To diagnose asymptomatic MBC might lead to longer use chemotherapy. Conclusions: Physicians should take symptomatic versus asymptomatic MBC into consideration in predicting prognosis to optimize treatment strategies.

scholarly journals Dynamics of Breast Cancer under Different Rates of Chemoradiotherapy

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Sara B. Mkango ◽  
Nyimvua Shaban ◽  
Eunice Mureithi ◽  
Twalib Ngoma
Keyword(s):  
Breast Cancer ◽  
Gene Therapy ◽  
Decay Rate ◽  
Hormone Therapy ◽  
Cause Of Death ◽  
Breast Tissue ◽  
Treatment Strategies ◽  
Common Cause ◽  
New Treatment ◽  
Treat Breast Cancer

A type of cancer which originates from the breast tissue is referred to as breast cancer. Globally, it is the most common cause of death in women. Treatments such as radiotherapy, chemotherapy, hormone therapy, immunotherapy, and gene therapy are the main strategies in the fight against breast cancer. The present study aims at investigating the effects of the combined radiotherapy and chemotherapy as a way to treat breast cancer, and different treatment approaches are incorporated into the model. Also, the model is fitted to data on patients with breast cancer in Tanzania. We determine new treatment strategies, and finally, we show that when sufficient amount of chemotherapy and radiotherapy with a low decay rate is used, the drug will be significantly more effective in combating the disease while health cells remain above the threshold.

scholarly journals The Role of Adipokines in Understanding the Associations between Obesity and Depression

2010 ◽  
Vol 2010 ◽  
pp. 1-6 ◽  
Author(s):  
Valerie H. Taylor ◽  
Glenda M. MacQueen
Keyword(s):  
Major Depression ◽  
Treatment Strategies ◽  
Physiological Role ◽  
Biological Mechanisms ◽  
Medline Search ◽  
New Treatment

Objective. Two major causes of disability, major depression and obesity, share overlapping psychosocial and pathophysiological etiologies. Studies are now focused on biological mechanisms linking the two illnesses, and there is interest in the role that adipokines may have in mediating the association between obesity and depression. We reviewed the literature to look at what is currently known about this association, focusing on the adipokines leptin, adiponectin, and resistin.Methods. A MEDLINE search, citing articles from 1966 onward, supplemented by a review of bibliographies, was conducted to identify relevant studies.Results. This paper identified plausible pathways underlying a link between adipokines and depression. Only a few studies have yet been conducted specifically examining these biomarkers in patients with depression, but the results are intriguing.Conclusion. This paper is one of the first to examine the association between adipokines and depression. It provides an overview of the physiological role of adipokines and summarizes the data suggesting that they may be dysregulated in major depression. This area of research may become increasingly important as new treatment strategies are developed.

Sign in / Sign up

Export Citation Format

Share Document